DEVICE AND TECHNIQUE FOR PERCUTANEOUS CLOSURE
OF VASCULAR PUNCTURE SITES
The present application claims priority from U.S. Patent Applications Nos. 60/111,438,
60/121,371, 60/129.959, and 60/143,251, which are all hereby incorporated by reference in
their entirety.
Field of the Invention
The present invention applies to techniques for achieving hemostasis after
percutaneous arterial puncture for any purpose, including but not limited to diagnostic
radiology and cardiology, as well as interventional radiology and interventional cardiology.
Background of the Invention
Certain medical procedures require intravascular access. In procedures such as cardiac
catheterization, counterpulsation and angiography, a catheter or other device is inserted into
an artery and fed through the vascular tree to the location of interest. Such procedures are
performed most commonly by percutaneous methods, and the access site most usually
selected is the groin, where the femoral artery is relatively accessible. However, other arterial
access sites as well as venous access sites are intended to be encompassed by the scope of the
present invention.
Such percutaneous procedures normally are performed by a Seldinger-type technique
consisting essentially of inserting an angiographic needle into the artery, followed by
inserting a guide wire through that needle into the artery. Thereafter the needle is removed
leaving the guide wire in place. Next, a sheath-dilator set is fed over the guide wire into the
artery in order to re-establish a vascular access route and to enlarge the opening sufficiently to
permit insertion of a catheter or other device. Thereafter, the dilator is removed and the sheath
or guide cannula remains in place during the procedure. A catheter or other device then can
be inserted through the cannula directly into the lumen of the artery.
After the procedure has been completed the catheter or other device, as well as the
sheath, is removed and the wound must be closed. Normally this is achieved by the
application of pressure to the skin and underlying tissue located above the vessel puncture
site. This is commonly applied by direct digital pressure by a medical professional, by a
pressure dressing or through the use of sandbags. With respect to arterial puncture sites,
customarily pressure is applied for at least lA hour, and frequently for much longer periods.
During this period the patient must be immobilized, lest movement interfere with the sealing
of the puncture site. Due to the amount of pressure required, the duration for which the
pressure is required, and the mandatory immobilization, the procedure is uncomfortable and
may be painful. Such patients also require the prolonged personal attention of a health-care
professional. Finally, puncture sites closed in this manner can reopen unexpectedly a
substantial period after wound closure apparently has been achieved, therefore patients often
are required to remain under close observation for prolonged time periods, which can
necessitate a hospitalization.
In an attempt to minimize such problems, physicians performing such procedures can
utilize the smallest caliber devices, often however a larger caliber device may be preferable
for many of these procedures. There is a need for an effective and simple means of achieving
reliable vessel puncture site closure under these circumstance.
A series of devices have been developed in an attempt tc address these problems.
Such devices attempt to achieve hemostasis through the application of a variety of means
once the procedure has been completed. Examples include those devices described in U.S.
Pat. Nos. 4,744,364, 4,852,568 and 4,890,612 to Kensey. These three patents describe a
mushroom or umbrella shaped device which is used to seal the artery from the inside. The
head of the device is placed within the arterial lumen and means are provided to pull and hold
the underside of the head against the inside wall of the lumen. It is believed, however, that
sealing from the inside can be the source of its own problems, including the promotion of clot
formation inside the vessel. Another method for sealing a puncture wound after removal of a
catheter is described in U.S. Pat. No. 4,929,246 to Sinofsky. The approach taken there is to
insert a balloon-tipped catheter into the tissue wound, inflate the balloon against the hole in
the artery and then use a laser to thermally weld the wound closed. Other approaches include
applying hemostatic material around the puncture site after completion of the procedure as
described in U.S. Pat, No. 5,437,631. U.S. Patent No. 5,478,352 to Fowler, describes a device
and method for closing a puncture by inserting a plug into the wound. This is performed after
the procedure is completed and the correct placement of the plug is achieved with the use of a
balloon catheter or cylindrical insertion device. U.S. Patent No. 5,437,631 to Janzen describes
a device for inserting collagen or other hemostatic materials into a puncture wound after a
blood vessel has been accessed and the puncture site enlarged by the insertion of a vascular
stent or dilator. U.S. Patent No. 5,725,498 to Janzen describes the placement of hemostatic
material against a punctured vessel wall after a procedure has been completed and requires
compression of the blood vessel as a part of the placement of the hemostatic material. U.S.
Patents Nos. 5,383,896 and 5,868,778 to Gershony et al. describe devices and methods to
effect closure of a blood vessel puncture site after completion of a procedure requiring the
insertion of an inflatable balloon device into the lumen of the blood vessel. U.S. Patents Nos.
4,838,280 and 5,080,655 to Haaga describe medical biopsy needles with bioabsorbable
gelatin tips and U.S. Patent No. 4,936,835 to Haaga describes a medical needle with a
bioabsorbable gelatin tip which can be deposited at biopsy or puncture sites and assist in
achieving hemostasis during a biopsy or venosection procedure. U.S. Patent No. 5,443,481 to
Lee describes a method of obtaining hemostasis after an intravascular procedure by applying
a hemostatic material to the area of the puncture site after the removal of the access device
used during the procedure. U.S. Patent No. 5,292,332 to Lee describes a device for sealing a
blood vessel puncture site by the insertion of a hemostatic plug into the vessel puncture site.
The present invention is believed to overcome most of the disadvantages of the previous
methods which require enlarging the blood vessel puncture site, removal of the access device
or both before any hemostatic material is placed..
Numerous materials and methods have been proposed for closure of arteries or other
blood vessels accessed during catheterization procedures. These various materials and
techniques include sutures, staples, cautery, plugs constructed of collagen, gelfoam, and other
biomaterials, slurries of microfibrillar collagen combined with procoagulants such as
thrombin, and fibrin glue. The ideal material would be thrombogenic, nonimmunogenic, and
bioresorbable, self-adhesive, radiopaque and would be of an appropriate viscosity to allow
precise placement outside the vessel wall with relatively little chance of inadvertent
placement of the material into the vessel lumen. For some devices, the use of a liquid, slurry,
gel, paste, or foam would be preferred over a solid material, since relatively more volume of
the former substances can be placed compared to the latter substance in low profile delivery
systems. The present invention addresses many of the problems with existing materials and
methods.
Summary of the Invention
The present invention comprises a vascular access device with a needle with an access
lumen, with which to obtain vascular access, at least one additional lumen for the infusion of
a hemostatic composition, and a means of infusing the composition at the site of vascular
access, in order to achieve hemostasis as part of an intravascular procedure. One embodiment
of the invention contains two or more infusion lumens, for the infusion of different
components of the hemostatic composition. The device is for use in any blood vessel that
would normally be used for such procedures, including arteries and veins. The infusion lumen
or lumens and the access lumen are arranged concentrically, or optionally in a parallel manner
adjacent to one another. In a concentric arrangement the infusion lumen or lumens are
arranged around the access lumen. In one preferred embodiment the infusion lumens
terminate in a mixing chamber, which optionally includes a mesh or a series of baffles to
permit more homogeneity via mixing of the components of the hemostatic composition.
The present invention includes a method of achieving hemostasis during an
intravascular procedure. The vascular access device of the present invention is inserted into a
blood vessel and advanced until the tip and opening of the access lumen is in the blood vessel
but the opening(s) of the infusion lumen(s) are adjacent to the exterior of the vessel wall.
Thereafter, the hemostatic composition is infused around the vascular puncture site, flow of
the composition into the vessel being prevented by the presence of the needle in the puncture
site. After the hemostatic composition is infused the vascular procedure is carried out in the
usual manner.
One embodiment of the invention comprises a vascular access device with a
hemostatic plug which is compressed and constrained by a deployment sheath, which is
removable by retraction or by being peeled away once the hemostatic plug is in the desired
location. The invention includes a method of using the vascular access device to achieve
hemostasis during an intravascular procedure. The access device is inserted and advanced
until the tip of the access lumen is in the lumen of the blood vessel. The access device is
further advanced until the hemostatic plug abuts the vessel wall and the deployment sheath is
then removed, allowing the plug to expand. The device then is removed, being replaced with
the usual type of device used for such intravascular procedures. The deployment sheath is of a
retractable or peel away design. In another embodiment, the device comprises a hemostatic
plug and deployment sheath as well as a lumen through which a guidewire can be fed. The
blood vessel is punctured and a guidewire inserted. Thereafter, the guidewire is inserted into
the lumen and the device is advanced over the guidewire until the plug is positioned against
the vessel wall. The deployment sheath is removed and the plug is permitted to expand.
Optionally, the device includes a channel or lumen through which extravasated blood can
flow when the plug is appropriately positioned against the vessel wall. Optionally, the
hemostatic plug of the present invention includes a removal filament for the removal of a
maldeployed plug.
The hemostatic compositions and plug are composed of compounds which can
achieve hemostasis, and include but are not limited to fibrin glue/thrombin, calcium
alginate/ionic calcium, sodium alginate/ionic calcium, collagen paste, or synthetic materials.
One embodiment of the present invention is the use of alginate compound for the purpose of
achieving hemostasis during intravascular and other medical procedures. These hemostatic
compounds contain a cationic salt, preferably calcium chloride, guluronic acid and/or
mannuronic acid and a liquid or other medium in order to produce a compound which is a
solid, a liquid, a gel, or a foam. Optionally the hemostatic composition or plug is rendered
radiopaque by the addition of contrast or other radiopaque material.
Brief Description of the Drawings
Other objects and many of the attendant advantages of the present invention will be
appreciated by a reading of the detailed description of the invention, especially when
considered in conjunction with the accompanying drawings, which are provided for
illustration and are not intended to limit the scope of the present invention.
FIG. 1 is a longitudinal cross sectional view of a first preferred embodiment of the invention
showing the construction of the infusion lumens but without the access lumen shown.
FIG. 2 A is a longitudinal cross sectional view of the first preferred embodiment with a side
by side arrangement of the access and infusion lumens
FIG. 2B is a longitudinal cross sectional view of a preferred embodiment with a co-axial
arrangement of the infusion and access lumens.
FIG. 2C is a transverse cross-sectional view of the device shown in FIG. 2B along plane 10.
FIG. 3 A is a longitudinal cross-sectional view of the distal end of a preferred embodiment
with a tri-axial arrangement of the lumens and with a mixing chamber.
FIG. 3B is a transverse section of the portion of the invention shown in FIG. 3A
FIG. 4 is aJongitudinal cross-sectional view of a second preferred embodiment of the present
invention comprising a hemostatic plug on the access device .
FIG. 5 is a longitudinal cross-sectional view of a preferred embodiment for the deployment of
a hemostatic plug after vascular access has been obtained
FIG. 6 is a longitudinal cross sectional view of the distal portion of another preferred
embodiment of the invention depicted in FIG. 5
FIGS. 7 A - G show various stages in the application of one preferred method of using the
device depicted in Figure 5
FIG. 7A shows a angiography needle inserted in a blood vessel, with a guidewire through the
bore of the needle.
FIG. 7B shows the guidewire in place after removal of the angiography needle
FIG. 7C shows the device of FIG. 5 being fed down the guidewire
FIG. 7D shows the hemostatic plug in place against the vessel wall.
FIG. 7E shows the expanded hemostatic plug after withdrawal of the deployment sheath.
FIG. 7F shows the plug in place after removal of the device
FIG. 7G shows the hemostatic plug in place with an angiographic sheath being fed over the
guidewire into the vessel after completion of the procedure.
Detailed Description of the Invention
The present invention applies to any technique which is performed using percutaneous
vessel (artery or vein) puncture including but not limited to diagnostic and interventional
radiology or cardiology. When an artery or vein is punctured, an opening in the vessel wall is
created and a catheter or other object is placed in the opening. This is usually but not always
performed, using a Seldinger-type technique. Subsequently, the vessel requires closure by
some mechanism. Existing devices for vessel closure are placed after insertion of and/or
removal of vascular catheters or sheaths, the placement of which result in the creation of large
holes within the vessel wall. Additionally, when existing devices are placed the exact location
of the vessel wall is not known, because the exact location of the vessel wall is only known at
the time of placing the puncture needle through the vessel wall and before the placement, for
example, of vascular catheters and sheaths.
One preferred embodiment of the present invention is a device for placing closure
materials, including but not limited to either single- or multi-component liquids, gels, or
slurries, immediately outside the vessel wall, while greatly reducing the risk of inadvertent
placement of the material into the lumen of the vessel. The vascular access device is an
improvement on arterial or venous entry needles, which are used to perform the initial blood
vessel puncture. Preferred embodiments of the vascular access device are shown in Figures
2A and 2B. Referring to Figure 2, the device which has a proximal end 30 and a distal end
20, comprises a needle 15, which is a hollow, preferably cylindrical metal device, with a
longitudinal bore or access lumen 7 extending from the proximal end 30 to the distal end 20.
At the distal end, the needle has a sharp tip 8 for penetration through the vessel wall and entry
into the vessel lumen. The present invention has one, additional longitudinally oriented
infusion lumen 1 , or optionally more than one additional longitudinally oriented infusion
lumen 2, which extend from the proximal portion of the device towards the distal end of the
device generally parallel to the access lumen, terminating with one, or optionally more than
one, opening 4 proximal to the distal opening of the access lumen 8. The distance from the
distal opening of the access lumen 8 to the distal opening, or optionally openings, of the
infusion lumen, or optionally lumens 4, preferably is from about 2 mm to about 10 mm, more
preferably from about 3 mm to about 6 mm, most preferably about 5 mm. As shown in Figure
2 A and in Figure 1, in one preferred embodiment of the present invention the various lumens
are arranged in a generally parallel manner adjacent to one another. In a second preferred
embodiment, depicted in Figures 2B and 2C, the lumens are arranged in a concentric manner,
co-axially in a device with two lumens, or optionally tri-axially in a device with three lumens.
Shown in Figure 2C is a cross-sectional transverse view along plane 10 in FIG. 2B, in this
embodiment, the access lumen 7 is the central lumen with a first infusion lumen 1 , and
optionally a second infusion lumen 2, arranged around the access lumen 7. Optionally, a
device will have two or more infusion lumens with distal openings that feed into a mixing
chamber 3, permitting the mixing of two or more components of a hemostatic composition.
The mixing chamber 3 comprises a short-segment chamber at the distal end of the infusion
lumens. An opening 4 in the mixing chamber allows mixed materials to exit near the needle
tip or distal end of the device, adjacent to the vessel and in close proximity to the vessel
puncture site. A more detailed cross-sectional view of the mixing chamber is shown in Figure
3A. Optionally, the mixing chamber has internal baffles or a mesh structure to provide more
homogeneous mixing of the hemostatic composition. Optionally, the distal opening of an
infusion lumen 4 has blunt edges. Additionally, optionally it is an aspect of the present
invention that there be a change in the caliber of the access device between the opening of the
access lumen and the opening of any infusion lumen, reducing the risk of accidental insertion
of the opening of an infusion lumen into the blood vessel lumen. In a preferred embodiment
the device is encased in an outer covering with a generally smooth contour. The proximal
opening 6 of an infusion lumen is connected to an infusion device (not shown) from which
the hemostatic composition is infused into the desired site. Optionally the infusion lumen
terminates with a means 5 of connecting the infusion lumen to an infusion device. An
example, which is not intended to limit the scope of the present invention, is a luer lock
device, which, optionally, is connected to an infusion device which includes but is not limited
to syringes and infusion pumps.
The present invention encompasses a method of employing the device to provide
hemostasis during intravascular procedures including but not limited to diagnostic
angiography and venography and therapeutic arterial and venous procedures. In this
embodiment of the invention, the access device is inserted optionally directly though the skin
and though the overlying tissue, into the selected blood vessel such that only the tip of the
device and the distal opening of the access lumen enters the blood vessel. An operator of
ordinary skill will recognize when the blood vessel has been puncture by its feel and by the
blood return at the proximal end of the access lumen. The operator is prevented from
inserting the device sufficiently deep into the blood vessel to allow an infusion lumen into the
blood vessel by the change in the caliber of the device between these openings, which
substantially increases the resistance to the deeper entry of the device into the blood vessel.
Optionally, the location of the opening of the infusion lumen outside the blood vessel lumen
is confirmed by aspiration through the infusion lumen to confirm the absence of blood return.
Once the blood vessel has been accessed, the hemostatic composition is infused. In a
preferred embodiment, optionally a guide wire is inserted through the access lumen into the
blood vessel to stabilize the device before the infusion of the hemostatic composition. In
contrast to prior methods, because the entry needle remains in place, the hole in the vessel
wall is extremely small and is effectively occluded by the needle itself, preventing the
delivery of the hemostatic composition into the lumen of the vessel. The hemostatic
composition is then injected through the infusion lumen or optionally lumens against, but not
into or through the vessel wall and puncture site. Once the hemostatic composition has been
placed the planned procedure is performed in the usual manner, with the optional placement
of dilators, sheaths, or other such devices. After completion of the procedure the various
devices are removed and the vessel puncture site is allowed to seal. The tract in the
hemostatic composition through which the various devices are placed is sealed by gentle
pressure, optionally elastic recoil of the composition, the flow of the composition into the
tract, or the clotting of blood within the tract. Optionally simple digital or other pressure is
applied.
The hemostatic composition optionally is thrombogenic, or acts simply as a physical
barrier. The present invention permits single- or multi-component liquids, gels, or slurries to
be injected near the distal end of the access device, just outside the punctured vessel, while
the entry needle is still in place through the vessel wall. Some compositions require multiple
components to achieve the proper thickness or firmness. Optionally, multiple infusion lumens
are included in this invention for this purpose. Suitable hemostatic compositions include, but
are not limited to biological agents including but not limited to fibrin glue/thrombin, calcium
or sodium alginate/ionic calcium, collagen paste, and synthetic materials. Additional
information about hemostatic compositions is disclosed below. Because these compositions
are most frequently in the form of a two part system which, after combination, forms a natural
barrier and closure seal, the present invention provides a method for precise mixing of multi-
component compositions immediately outside the vessel wall for rapid use in percutaneous
vessel closure.
The mixed multi-component composition will harden according to its normal
properties immediately outside the vessel and cover the vessel puncture site, effectively
closing and sealing the site from further injury or exposure. The sealant material is soft
enough to allow passage of a catheter, sheath, and/or vessel dilator that may be placed over a
guide wire after removal of the entry needle. At the end of the medical procedure which
necessitated vessel puncture, the catheter/sheath is removed and the material remains in place
just outside the vessel. Any tract that was created through the material by the catheter/sheath
is closed by limited indirect manual pressure, by clotting of blood in the tract, or by elastic
recoil of the material to close down to its size at the time of the initial deposition. The
composition material is biocompatible and bioresorbable and can be rendered radio-opaque to
allow visualization on fluoroscopy. Over time, the bioresorbable hemostatic composition will
dissipate from the closed site, eliminating any requirement for manual removal.
The dimensions for the preferred embodiments of the device include a diameter 21 of
up to about 5 millimeters (15 French) for the whole device, more preferably a diameter of
about 2 millimeters or less (6 French or less) and lumen diameters of about 1 millimeter (3
French), more preferably of about 0.5 millimeter.
Figure 1 provides a drawing of a cross sectional view of the infusion lumen
arrangement in a side by side configuration in one preferred embodiment of the device, to
demonstrate a two-part sealant delivery vehicle. The needle lumen is not shown. Components
1 and 2 of the hemostatic composition are provided by tubing coming from individual
reservoirs and linked to the infusion lumens by any commercially available hub or connector.
The lumens 1 and 2 are connected in a side by side configuration and are linked to the mixing
chamber 4 at the distal end 20 and to the reservoirs at the proximal end 30, either in a one
piece design as shown or via commercially available needle ports (not shown). Optionally,
the mixing chamber 3 is baffled or contains a mesh-like material (not shown) to improve
mixing.
Figure 2 shows an example of two component devices whereby the infusion lumens 1
and 2 are attached to the needle lumen 7 in either a side by side configuration (Figure 2A) or
a coaxial or tri-axial configuration (Figure 2B). Reservoir connections 5 and tubing 6 are
shown at the top of the device and the reservoirs are not shown but optionally include glass or
plastic syringes. The mixing lumen 3 is located near the tip 8 of the needle containing the
access lumen 7.
Figure 3 A shows an longitudinal cross section of the distal portion of a coaxial
embodiment of the present invention. FIG. 3B shows the cross section of the device at level
1 1 of FIG. 3 A. The needle tip 8 and needle or access lumen 7 are shown. Infusion lumen 1
surrounds the needle and infusion lumen 2 surrounds infusion lumen 1. The mixing chamber
3 is shown at the end of the two infusion lumens 1 and 2 and is located near the needle tip 8.
Baffles or mesh (not shown) optionally are located in the mixing chamber 3 to increase
turbulence and improve mixing of the sealant components.
Another preferred embodiment of the present invention, shown in Figure 4
incorporates a solid hemostatic plug 12 as well a method of using the invention. This
embodiment of the invention comprises a solid expansile hemostatic plug 12 , shaped with a
slightly blunted distal end 31 to permit positioning against a blood vessel wall puncture site
without penetrating the blood vessel wall with the plug. Optionally, the plug has a
longitudinally oriented lumen 23 in the approximate center of the plug 12 or at the edge of the
plug 12. A needle or other access device 15 passes through the lumen. The plug is surrounded
circumferentially by a removable coaxial deployment sheath 13 which optionally provides
support, protection and/or lubricity during the placement of the plug. The tip of the
deployment sheath 32 is slightly tapered, but is not so tapered that it will allow passage into
the artery. The needle 7 or optionally other access device is capable of being used to access a
blood vessel, with the access device tip 8 being inserted within the blood vessel. The
deployment sheath 13 is removable and is of a retractable, or optionally of a tear-away
design. Exposure of the plug 12 in the deployment location after removal of the deployment
sheath 13 permits it to expand and contribute to hemostasis. Optionally, the plug 12 is wetted
with a radiopaque or other liquid before insertion.
The present invention includes a method of using this embodiment to provide
hemostasis during intravascular procedures including but not limited to diagnostic
angiography and venography and therapeutic arterial and venous procedures. In this
embodiment of the invention, the access device is inserted optionally directly though the skin
and though the overlying tissue, into the selected blood vessel such that only the tip of the
device and the distal opening 8 of the access lumen enters the blood vessel. An operator of
ordinary skill will recognize when the blood vessel has been puncture by its feel and by the
blood return at the proximal end 30 of the access lumen. The operator is prevented from
inserting the device sufficiently deep into the blood vessel to force the plug 12 and
deployment sheath 13 into the blood vessel by the change in diameter between the tip of the
access lumen 8 and the plug 12 with the deployment sheath 13. Once the blood vessel has
been accessed, the hemostatic plug 12 is advanced to the desired location against the vessel
wall. In a preferred embodiment, optionally a guide wire is inserted through the access lumen
into the blood vessel to stabilize the device before the hemostatic plug 12 is moved into
position. Because the entry needle 7 remains in place, the hole in the vessel wall is extremely
small and is effectively occluded by the needle itself, assisting in preventing hemostatic plug
12 from being forced into the lumen of the vessel. When the hemostatic plug 12 is in the
desired location the deployment sheath 13 is removed optionally by withdrawing it, or if it is
of the optional peal away design, by peeling it away. Once the hemostatic plug 12 has been
placed the planned procedure is performed in the usual manner. The optional placement of
dilators, sheaths, or other such devices is performed by inserting such devices over a
guidewire through the hemostatic plug 12. After completion of the procedure the various
devices are removed and the vessel puncture site is allowed to seal. The tract 23 in the
hemostatic plug 12 through which the various devices are placed is sealed by gentle pressure,
optionally elastic recoil of the plug 12, the clotting of blood within the tract 23 or by other
means. Optionally simple digital or other pressure is applied.
Another embodiment of the present invention pertains to a solid hemostatic plug 12 as
shown in Figure 5 for use after the blood vessel has been accessed, a guidewire inserted, and
the insertion device removed. As shown in Figure 5, this embodiment comprises a solid
expansile hemostatic plug 12 shaped with a slightly blunted distal 31 end to permit
positioning against a blood vessel wall puncture site without penetrating the blood vessel wall
with the plug 12. The invention has a channel or lumen 35 through which the guidewire is fed
and used to guide the plug 12 to the desired location against the blood vessel wall. Optionally
the lumen 35 is formed by a tapered vessel dilator. Preferably, the lumen 35 is formed by a
catheter, stent or dilator of a flexible material. The embodiment preferably comprises a
stability rod 36, preferably of a plastic material, which aids in directing the plug 12 to the
desired location and optionally assists in maintaining it at that location during the removal of
the device. The plug 12 is surrounded circumferentially by a removable coaxial deployment
sheath 13 which optionally provides support, protection and/or lubricity during the placement
of the plug. The tip 32 of the deployment sheath 13 is slightly tapered, but is not so tapered
that it will allow passage into the artery. The deployment sheath 13 is removable and is of a
retractable, or optionally of a tear-away design. Exposure of the plug 12 in the deployment
location after removal of the deployment sheath 12 permits it to expand and contribute to
hemostasis. Optionally, the plug 12 is wetted with a radiopaque or other liquid before
insertion. As shown in Figure 6, optionally, the preferred embodiment shown in figure 5
incorporates a longitudinal channel or lumen 16 through which extravascular blood can flow
proximally after entering its distal opening 15 when the vessel wall is punctured and blood is
extravasated, indicating appropriate positioning of the plug 12 against the vessel wall. The
invention is designed to permit the needle 7 or other access device to be withdrawn easily,
leaving the plug 12 in position. Optionally, the invention comprises a removal filament (not
shown) which is attached to the plug, permitting withdrawal of a malpositioned plug.
The present invention also comprises a method of using this preferred embodiment.
This is illustrated in figures 7A to 7G which are provided only for illustration and are not
intended to limit the scope to the present invention. In one preferred embodiment the selected
blood vessel is accessed with an angiography needle 50. The needle 50 is inserted, optionally
directly through the skin 40 and, through overlying tissue, and the tip is inserted through the
vessel wall so that the lumen is located within the blood vessel lumen 41. The location of the
needle tip within the lumen of the vessel 41 is indicated by a blood return flowing through the
access lumen and visible at the proximal end of the needle. Thereafter a guide wire 42 is
inserted through the access lumen into the blood vessel lumen as depicted in Figure 7A. The
angiography needle 50 is then removed leaving the guidewire 42 in place as shown in Figure
7B. Thereafter, the device is moved into position by feeding the guidewire 42 through the
access lumen 7 and advancing the device over the guidewire 42 as shown in Figure 7 C. The
device is moved into position but the plug 12 is prevented from entering the vessel lumen 41
by the slightly blunt tip of the plug 12 and deployment sheath 13 as depicted in Figure 7D.
The deployment sheath 13 is advanced to the measured distance, or until resistance is felt, or
optionally until blood is seen to emanate from the device as dύ tiled below. At this time, the
deployment sheath 13 (which may be peel-away or retractable) is removed and the plug 12 is
deployed and is allowed to expand as depicted in Figure 7E. Optionally the device is then
removed leaving the plug 12 and guidewire 42 in place as shown in Figure 7F. Preferably the
angiography sheath 51 which comprises part of the device is then advanced into position in
the blood vessel 41 as depicted in Figure 7G. The dilator/sheath system 51 used for such
vascular procedures preferably is placed by being fed over the guide wire 42 that is inserted
through the longitudinal lumen7 that exists in the plug. Optionally, the catheter/sheath 51
may pass adjacent to the plug 12 . At the end of the procedure, the sheath 51 is removed and
manual pressure held over the site. The plug 12 is prevented from penetrating the vessel wall
by the slightly blunt nature of the distal end of the plug 12.
The material comprising the hemostatic plug is biocompatible and reabsorbable.
Immediate additional angiography through the same site is possible if necessary. In a
preferred embodiment the material is thrombogenic, relatively soft, and optionally mildly
adhesive. Optionally the material is radiopaque due to the addition of radiopaque material
including but not limited to barium, iodinated contrast medium, tantalum and tungsten.
Suitable materials include but are not limited to collagen fibrin glue/thrombin, calcium or
sodium alginate/ionic calcium, and synthetic materials.
Optionally, the device contains a port for injection down the barrel of the device to
allow wetting of the plug with iodinated contrast material prior to deployment or optionally
after placement but before removal of the deployment sheath, to allow direct imaging of the
plag after deployment.
The devices of the present invention optionally are disposable or re-usable and are
preferably .made from materials which may be sterilized, including but not limited to metals,
plastics or composite materials such as ceramics, or any combination of such materials. A
preferred material for use is surgical grade stainless steel for rigid components and surgical
grade polyethylene for flexible components. Optionally, Teflon or other protective coatings
may be used in areas where there is contact with the hemostatic composition. Optionally the
invention is provided to the user packaged in a pre-loaded, pre-sterilized form.
The present invention also comprises the use of alginate derivatives for use as vessel
closure materials, as hemostatic compositions, and as hemostatic plugs as defined herein or in
other wound closure applications.
Alginate, a biomaterial derived from seaweed, is a polysacharride of d-manuronic acid
and 1-guluronic acid that forms a viscous solution when dissolved in 0.9% saline and gels
immediately upon contact with divalent cations such as calcium. Alginate derivatives, either
liquid or solid, have not previously been used as a material for vessel closure applications.
Alginate is considered an appropriate material for vessel closure because alginate derivatives,
specifically calcium alginate supplied as a (solid) woven wound dressing, have been shown to
be thrombogenic, nonimmunogenic and bioresorbable. Alginate salts such as calcium alginate
or sodium alginate can be produced with varying viscosities. In addition, combining the
alginate material with radiopaque materials, thrombogenic materials, and bioadhesives can
further enhance its performance as a closure material.
Alginate is most commonly supplied as either sodium alginate or calcium alginate,
and may have a preponderance of either the guluronic acid or mannuronic acid derivatives,
with higher proportions of guluronic acid providing increased gel strength relative to
alginates with a preponderance of mannuronic acid. Also, sodium alginate is soluble in water,
however upon increasing the proportion of calcium counterions insoluble alginate salts are
generated. The thrombogenicity of alginate is felt to be dependent on the calcium ions that
stimulate thrombus formation. Thus, when used as a closure material, the alginate would by
necessity contain at least some amount of calcium alginate either alone or in combination
with sodium alginate. To achieve the proper viscosity of the material, the proportion of
guluronic acid will vary in a range from about 0.1% by weight to about 10% by weight.
The material may be supplied as a single component which would be prepared
immediately prior to use, or may be delivered to the outer surface of the vessel wall through a
multicomponent delivery system such as is described herein, with the various delivery
components carrying 1 ) the alginate salt, optionally sodium alginate, calcium alginate, or
both; 2) a solution containing ionic calcium, to mix with the alginate salt and stimulate
insoluble gels to result in an increased viscosity of the mixed components and for use as a
closure material; and optionally 3) radiopaque materials such as barium, iodinated contrast,
tantalum, or tungsten; and optionally 4) a bioadhesive and/or a thrombogenic material to
enhance overall performance of the material as a closure material. The alginate material is
supplied as a liquid of either low or high viscosity, a gel, a foam, or a slurry, while the
remaining components (2-4, above) are supplied as liquids. Items under (4) above optionally
are directly mixed with the alginate material before addition into the delivery system. The
materials listed above (1-4) are infused by multiple infusion devices into multiple infusion
lumens of the present invention to deliver the components adjacent to the outside of a vessel
wall. Optionally the components are mixed together before being placed into the infusion
device and infused through the infusion lumen(s)Optionally the material is used in other
devices for other hemostatic applications.
Optionally, bioadhesives and thrombogenic materials are added to the alginate salts to
increase rates of healing and closure. In one embodiment of the present invention formulated
alginate salts of appropriate viscosity are packaged in pre-sterilized delivery devices,
providing surgeons and other physicians with a non-invasive, rapid, bioabsorbable means for
closing vascular wounds or punctures. In accordance with one embodiment, a vessel closure
material is provided. The material comprises an alginate salt compositions containing varying
proportions of the sodium alginate salt, calcium alginate salt, guluronic acid, or mannuronic
acid and a medium such as water so as to achieve appropriate physical characteristics of a
liquid, gel, slurry, foam, or solid.
Listed below are a series of examples of the present invention. The examples
contained herein are intended to illustrate the invention but are not intended to limit the scope
of the invention.
Example 1 Coaxial Needle Design for Placement of Injectable Solutions
A device of the present invention was constructed utilizing two different types of
arterial entry needles. They are "single-wall" entry needles that have a beveled tip 8 and no
inner stylet. Each of these needles are approximately 5 cm length and have a luer-lock hub
attached. One needle was approximately 0.052" outer diameter and 0.035" inner diameter 7
(1-part arterial needle, Inrad, Kentwood, MI), while the other was approximately 0.030" outer
diameter and 0.018" inner diameter. (Micropuncture introducer needle, Cook, Inc,
Bloomington, IN)
Coaxial sheaths were constructed either from modification of commercially-available
arterial sheaths. (4 Fr arterial sheath, Cordis Endovascular, Miami Lakes, FL) or from
welding of metallic sheaths to the outer portion of the needles. The sheaths used were 4 Fr
inner diameter and were cut to a length that, when the needle was placed through the
diaphragm of the sheath, the end of the sheath rested approximately 5 mm from the needle
tip. The arterial sheath had a side-port attached to its proximal portion that allowed injection
of liquids and slurries, and a diaphragm that allowed a water-tight seal around a needle placed
through the diaphragm lumen. Subsequently, a smooth, tapered transition from the outer
surface of the needle to the outer surface of the sheath was achieved by placing a plastic
shrink-wrap tube over the needle-sheath transition and heating the wrap to conform to the
needle-sheath transition. (Heat Shrinking Tubing, Multi-purpose Flexible Polyolefine, 1/16th
and l/8th inchJM Electric, Austin, TX) Small holes, approximately 1 mm diameter, were cut
in the shrink-wrap plastic to allow efflux of the hemostatic composition.
Another prototype design consisted of a metallic outer sheath welded to the outer
portion of the needle, with a smooth transition between the outer portion of the needle and the
distal portion of the coaxial lumen. A side-port was attached to the proximal portion of the
outer lumen to allow injection of liquid materials.
Example 2 Method of Using Invention
Using both canine and swine models, the needle-sheath constructs were placed using
percutaneous technique into the common femoral artery, as evidenced by pulsatile blood
return through the needle lumen. Guidewires (either 0.035" or 0.018", depending on the
prototype design) were placed through the lumen of the needle into the femoral artery.
Hemostatic compositions were prepared on the bench. Components have included collagen
slurries, collagen slurries mixed with thrombin, avitene mixed with thrombin, fibrin glue
mixed with thrombin, and alginate mixed with calcium solutions. In all cases, the materials
were rendered radiopaque, ie, visible on X-ray imaging, by addition of approximately 20-30
volume percent of iodinated contrast medium (Omnipaque 300, Nycomed, Princeton, NJ).
After placement of the wire and preparation of the material, 3 mL of the hemostatic
composition was injected down the lumen. X-ray imaging was performed throughout
injection to confirm that the material remained immediately outside the vessel lumen without
penetration into the arterial lumen.
Following injection of the material, the needle apparatus was removed and arterial
sheaths and catheters were placed over the indwelling wire, through the hemostatic material,
into the arterial lumen. Systemic anticoagulation was achieved with intravenous injection of
heparin. Subsequently, the sheaths and catheters were removed and manual pressure applied
to the site to achieve hemostasis. Hemostasis was achieved even in the setting of systemic
anticoagulation, which is typically impossible without placement of hemostatic devices.
Example 3 Hemostatic Compositions
A variety of hemostatic compositions were made for infusion.
Hemostatic Composition A:
A collagen slurry was made of bovine Type 1 collagen (Bovine type 1 collagen,
Collagen Matrix, Inc, Franklin Lakes, NJ), fabricated into an injectable slurry. This was used
alone (approximately 3 mL total) or mixed with 10,000 U bovine thrombin (Jones Pharma
Inc., St. Louis, MO) dissolved in 2 mL sterile water (equal proportions of collagen and
thrombin solution for total of 3 mL).
Hemostatic Composition B:
Avitene (microfibrillar collagen hemostat, MedChem Products, Inc, Woburn, MA)
was mixed with sterile water to achieve a viscous solution and mixed with 10,000 U bovine
thrombin dissolved in 2 mL sterile water, using equal portions of the avitene and thrombin for
a total of 3 mL.
Hemostatic Composition C:
Fibrin glue, obtained from human donors in the usual concentration, (Cathet.
Cardiovasc. Diagn. 1997 May;41(l):79-84) was mixed with 10,000 U bovine thrombin
dissolved in 2 mL sterile water, using equal portions of the fibrin glue and thrombin
solutions, for a total of 3 mL.
Hemostatic Composition D:
1.0% sodium alginate (guluronic acid) (Pronova Biomedical, Oslo, Norway) was
mixed with equal volume of 50 mMol calcium chloride, (Fisher Scientific, Fairlawn, NJ) to a
total volume of 3 mL of Alginate solution.
Example 4 Hemostatic Plug Device
A 2 mm inner diameter plastic shrink-wrap tube was modified to render one end of
the tube smoothly tapered to a diameter of 1 mm by heating with a match and shaving to
smooth
taper. A longitudinal slit then was made in the tube. A 2 cm diameter, 30 mm length
expandible collagen plug (J. Vase. Interv. Radiol. 1998 Jul-Aug;9(4):656-9) was loaded into
the tube and soaked in iodinated contrast medium (Omnipaque 300, Nycomed, Princeton,
NJ). A 19 g arterial entry needle (1-part arterial needle, Inrad, Kentwood, MI) was placed
through the collagen plug and out through the tapered end of the tube. The needle was
advanced into the femoral artery and a guidewire was placed. The tube was retracted, and its
longitudinal slit allowed retraction of the tube with retention of the collagen plug at the
arterial wall. The needle was removed, a sheath placed, and then subsequently removed.
Example 5 Hemostatic Plug for Placement after Access Needle Removal
A 14 F peel-away sheath with a dilator (14 Fr peel-away sheath-dilator, Daig,
Minnetonka, MN), was modified for use as a closure device. The dilator was removed, and
its distal end was cut to render a blunt surface. A pad of Gelfoam, (Gelfoam absorbable
gelatin sponge, Pharmacia and Upjohn Co., Kalamazoo, MI) approximately 2 cm x 2 cm x
0.6 cm was flattened and rolled up to fit into the distal end of the peel-away sheath. After
placement of the gelfoam, the cut dilator was placed into the sheath, with the blunt end of the
dilator resting along the proximal aspect of the rolled gelfoam pad. Iodinated contrast was
injected down the lumen of the dilator to soak into the gelfoam. A needle was placed into the
femoral artery of a pig, a 0.035" wire was placed into the artery, the needle was removed, and
the sheath/gelfoam/dilator apparatus was loaded onto the wire by passing the proximal end of
the wire through the gelfoam and then through the inner lumen of the dilator. The apparatus
was passed through the subcutaneous and deeper tissue planes until resistance was
encountered, indicating the distal aspect of the device rested on the artery. The peel-away
sheath was removed while forward pressure was applied to the dilator, to ensure that the
gelfoam would not be pulled superficially during removal of the peel-away sheath. The plug
expanded in situ, as evidenced by X-ray imaging. The sheath/dilator system was removed, a
tapered dilator/sheath was placed over the wire, through the plug, into the artery. The system
was then removed, leaving the plug in place, and hemostasis was achieved even in the setting
of systemic anticoagulation.
While the preferred forms of the present invention are described and illustrated herein,
it will be obvious to those skilled in the art that various changes and modifications may be
made therreto without departing from the scope of the present invention . Therefore the
descriptions above and the accompanying drawings should be interpreted as being
illustrative and not intended to limit the scope of the present invention.